Evaluation of Once a Day of Arbekacin Administration to Neonates as a New Object of Peak Concentration

DOI Web Site Web Site 1 Citations 21 References

Bibliographic Information

Other Title
  • 新しい推奨ピーク値を目標とした新生児に対するアルベカシン 1 日1 回投与法の検討
  • アタラシイ スイショウ ピークチ オ モクヒョウ ト シタ シンセイジ ニ タイスル アルベカシン 1ニチ 1カイ トウヨホウ ノ ケントウ

Search this article

Abstract

Once a day of arbekacin（ABK）administrations based on a new object of peak concentration setting on 9-20μg/mL were performed to 14 neonates. The gestational ages were 27.3±4.2 weeks. As to the preparing initial dosage, Therapeutic Drug Monitoring Program soft was used. Mean daily dose of 6.2±0.4mg/kg body weight was administered every 24 to 48h by 30 min intravenous infusion. Mean serum peak concentrations of ABK and those of trough concentrations were 15.2±4.3μg/mL and 2.0±1.4μg/mL respectively. The relationship between the measured values（y）and predicted values（x）showed the regression equation y＝0.969＋0.931x（R2＝0.769, n＝35），which suggested the usefulness of the dosage design. Overall clinical effectiveness was 78.9％（11/14）. There were no obvious adverse effects including abnormal auto auditory brainstem responses and serum creatinine increase. Effectiveness rate and no adverse effects suggested that once a day of ABK therapy in neonate including extremely preterm infant was preferable regimen.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 84 (6), 727-733, 2010

    The Japanese Association for Infectious Diseases

Citations (1)*help

See more

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top